Revolution Meds partners with AI specialist Iambic

US late-stage oncology-focused Revolution Medicines (Nasdaq: RVMD) and Iambic Therapeutics, which is developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models.

In this multi-year agreement, Iambic will use structures and molecular libraries provided by Revolution Medicines to train bespoke versions of NeuralPLexer, Iambic’s industry-leading model for protein-ligand structure prediction. Revolution Medicines will also have access to Iambic’s PropANE model, a pre-trained graph neural network deployed across dozens of drug properties for lead selection and optimization. Iambic will receive up to $25 million through upfront and near-term performance-based milestone payments, plus ongoing research and development reimbursements.

“We are impressed with the Iambic team and the potential of their platform to enable the discovery of novel compounds on behalf of Revolution Medicines' portfolio,” said Dr Mark Goldsmith, chief executive and chairman of Revolution Medicines. “The capabilities of Iambic’s AI-driven discovery platform, partnered with our unique collection of proprietary data, present an opportunity to rapidly explore oncology targets known to be challenging to address through conventional drug discovery approaches,” he added.